CN100500192C - Medicine for treating eye vitreous hemorrhage and turbidity and its preparation method - Google Patents
Medicine for treating eye vitreous hemorrhage and turbidity and its preparation method Download PDFInfo
- Publication number
- CN100500192C CN100500192C CNB2004100236491A CN200410023649A CN100500192C CN 100500192 C CN100500192 C CN 100500192C CN B2004100236491 A CNB2004100236491 A CN B2004100236491A CN 200410023649 A CN200410023649 A CN 200410023649A CN 100500192 C CN100500192 C CN 100500192C
- Authority
- CN
- China
- Prior art keywords
- medicine
- radix
- hematocele
- eye vitreous
- vitreous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Disclosed is a medicine for treating eye vitreous hemorrhage and turbidity and its preparation method wherein the medicine comprises (by weigh ratio) 7-17% of red sage root, 4-11% of root bark of tree peony, 4-11% of radix paeoniae rubrathe, 4-8% of cattail pollen, 4-11% of motherwort fruit, 11-25% of dried rehmannia root, 4-11% of Chinese angelica root, 6-12% of sea tangle, 7-17% of eclipta, 2-5% of dragon's blood resin, and 4-11% of mushroom.
Description
(1) technical field: the present invention relates to a kind of medicine and preparation method thereof, especially a kind of medicine for the treatment of eye vitreous hematocele, muddiness and preparation method thereof.
(2) background technology: at present, to the treatment of the vitreous hemorrhage of eyes, vitreous opacity, retinal hemorrhage, hyphema etc., clinical urokinase commonly used, Operand are main, and promoting the dissipation and the absorption of hematocele, but clinical efficacy is not good enough.It is best to use effect in 2-3 week after urokinase is preferably in and hinders.Because this phase state of an illness is more stable, can not cause accidents such as the secondary glass body is hemorrhage, iodine reagent is mainly used in the retinal hemorrhage in late period, vitreous hemorrhage or muddiness.All has limitation aspect result of use or operating period.Carried out operation on vitreous in recent years, for the treatment of primary disease provides new method, but this operation can not be in the morbidity early implementation, and postoperative has severe complications, as recurrent vitreous hemorrhage, crystal muddiness in various degree etc., someone removes hematocele with vitrectomy in early days, complication is serious and incidence rate is high, and this surgical apparatus costs an arm and a leg, and basic hospital is difficult to popularize and use, the surgery cost height, part patient is difficult to accept.
(3) summary of the invention: the deficiency that the objective of the invention is to overcome above-mentioned prior art, and provide a kind of low price, taking convenience, have no side effect, easily accepted medicine of disease of eye such as the effective treatment eye vitreous hematocele that is difficult for developing complications, vitreous opacity, retinal hemorrhage, hyphema and preparation method thereof by the patient.
Purpose of the present invention can reach by following measure: the medicine of treatment eye vitreous hematocele, muddiness is characterized in that it is the medicament of being made by following raw materials by weight proportions: 7～17% Radix Salviae Miltiorrhizaes, 4～11% Cortex Moutans, 4～11% Radix Paeoniae Rubra, 4～8% Pollen Tyjphae, 4～11% Fructus Leonuris, 11～25% Radix Rehmanniae, 4～11% Radix Angelicae Sinensis, 6～12% Thallus Laminariae (Thallus Eckloniae)s, 7～17% Herba Ecliptaes, 2～5% Sanguis Draxonis, 4～11% Lignum Dalbergiae Odoriferaes.
Treatment eye vitreous hematocele, the preparation method of muddy medicine, it is characterized in that crude drug: Radix Salviae Miltiorrhizae with constant weight percentage ratio, Cortex Moutan, Radix Paeoniae Rubra, Pollen Tyjphae, Fructus Leonuri, Radix Rehmanniae, Radix Angelicae Sinensis, Thallus Laminariae (Thallus Eckloniae), Herba Ecliptae, Sanguis Draxonis, Lignum Dalbergiae Odoriferae adds 4～8 times water logging bubble at least 30 minutes, decoct 2 times, the time of twice decoction was respectively 1.5～2.5 hours and 1～2 hour, merge decocting liquid twice, filtering and concentrating, be cooled to room temperature, add ethanol and make and contain alcohol amount and reach 65～70%, leave standstill and make it abundant precipitation more than 24 hours or 24 hours, get supernatant liquid filtering, decompression filtrate recycling ethanol, add the sodium benzoate aqueous solution, adding distil water transfers to full dose, stirs evenly.Ethanol is 95% alcoholic solution, and the sodium benzoate aqueous solution is 0.4% aqueous solution.Adding distil water transfers to full dose and is meant that the gross weight of filtrate adding distil water is the summation of crude drug weight.
Treatment eye vitreous hematocele, muddy medicine can also reach by following measure: it is characterized in that it is the medicament of being made by following raw materials by weight proportions: 10～15% Radix Salviae Miltiorrhizaes, 5～10% Cortex Moutans, 5～10% Radix Paeoniae Rubra, 5～7% Pollen Tyjphae, 5～10% Fructus Leonuris, 15～22% Radix Rehmanniae, 5～10% Radix Angelicae Sinensis, 7～11% Thallus Laminariae (Thallus Eckloniae)s, 10～15% Herba Ecliptaes, 2～5% Sanguis Draxonis, 5～10% Lignum Dalbergiae Odoriferaes.The medicine of treatment eye vitreous hematocele, muddiness is characterized in that described medicament is an oral liquid.
Compared with the prior art the present invention has following good effect:
30 eyes of traumatic vitreous hemorrhage 30 examples of Drug therapy of the present invention, effect is satisfied, and compares observation with 30 eyes of 30 examples of carbazochrome salicylate, potassium iodide treatment, and the result is as follows:
Experimental animal: Kunming mouse, Shandong Chinese medicine institute animal housing provides, quality certification Shandong kinoplaszm word 960104 rats, Shandong Province's epidemic prevention station provides, quality certification Shandong kinoplaszm word 960103 new zealand rabbits, epidemic prevention station animal housing in Shandong Province's provides.
Zoopery:
Influence to mice whole blood concentration:
Select 12 monthly ages health to plant 40 of Mus, be divided into 4 groups, give medicine 10 ml/kg of the present invention, 20 ml/kg, water 10 ml/kg respectively, twice of every day, fasting is 8 hours before the successive administration 10 days, last administration, and 2 hours eyeball rear vein beards are got blood behind the medicine, the anti-condensation cone and plate viscometer of heparin is surveyed whole blood viscosity, its result such as following table
Compare * P＜0.05**P＜0.01 with the water matched group
Body weight is 32 of the rabbit of 1.5-2 kilogram, be divided into 4 groups at random, every group 8, be respectively medicine 5 ml/kg of the present invention, 10 ml/kg, four groups of water 10 ml/kg and FUFANG DANSHEN ZHUSHEYE 1 ml/kg, the anesthesia of 35 milligrams/pentobarbital of rabbit utilizes laser microcirculation kinetic analyzer to measure its right outside binding film microcirculation, and per second is measured once, get meansigma methods 5 times, as measured value, measure and respectively organize rabbit, administration respectively, medicine of the present invention and water matched group are by duodenal administration, Radix Salviae Miltiorrhizae Injection is by the auricular vein administration, and medicine of the present invention and water matched group after administration 90 minutes give 10% macromolecule Leucoglucosan 6 ml/kg by auricular vein, behind the iv 30 minutes the time, measure co-located microcirculation magnitude of voltage once more, (probe maintains static), the Radix Salviae Miltiorrhizae Injection group is behind the medicine 60 minutes, measure when giving behind the Leucoglucosan 30 minutes, medicine of the present invention is as shown in the table to the influence result of rabbit bulbar Conjunctiva Microcirculation:
Compare * P＜0.05 with the water matched group
Experimental result prompting medicine of the present invention has tangible promotion and protective effect to rabbit conjunctive bulbi microcirculation, improves the magnitude of voltage of the microcirculatory blood flow of " blood stasis " model rabbit.
To the microcirculatory influence of mice pia mater encephali:
48 of mices, male and female half and half are divided into 4 groups at random, administration is the same respectively, successive administration 3 days, and the last administration is after 90 minutes, 40 minutes barbital sodium injecting anesthetics of mice are peeled off head skin, muscle and skull, 37 degree insulations, microcirculation probe is placed the left side mantle, behind tail intravenously administrable 15 microlitres/kilogram pituitrin 2 minutes the time, mensuration microcirculation magnitude of voltage, continuous 5 times (1 time/second) averages, to mice pia mater encephali microcirculatory blood flow to influence the result as shown in the table
The experimental result prompting, medicine of the present invention has significant protective effect to mice pia mater encephali microcirculation, increases lobus posterior hypophyseos mice pia mater encephali blood flow.
Clinical research:
Observed case is the court's outpatient service and ward inpatient.Vitreous hemorrhage is divided into four types by damage reason: the simple contusion; Perforating wound of sclera; Intraocular foreign body; Eyeball rupture is hindered.Prescription on individual diagnosis and inpatient respectively are divided into two groups at random by each type of impairment, and odd number order person is the A group, and even number order person is the B group.
Clinical data relatively sees Table 1-3, is found out two groups the relatively more equal no significant difference (P＜0.05) of age, the course of disease by table 1.
Two groups of patient clinical datas of table 1 relatively
Two groups of patient's cause of disease statistics
| The ocular injury type |
| Group is dampened perforating wound of sclera intraocular foreign body eyeball rupture merely and is hindered |
| A 24 2 2 2 B 24 2 2 2 |
Vision distributes before and after two groups of patient treatments of table 3
| The manual index 0.02-of unglazed sensitization sense 0.1-0.3-0.5 0.8-1.0-before and after the group treatment |
| 1021061757 B front 0785221212 rear 1232344533 behind the A front 1588130202 |
Treatment back vision increases more than 0.1 26 eyes of Chinese drug-treated group (86.7%), 19 eyes of matched group (63.3%).
Diagnostic criteria:
Vitreous hemorrhage by ophthalmofundoscope, three mirror contact lens, eye ultrasound diagnosis, is divided into following level Four with reference to 1980 stage divisions that propose:
I level hematocele scope is less than being/4 quadrants, and the optical fundus is slightly dim, and structure is easily seen.
About 1/2 quadrant of II level hematocele scope, the optical fundus height is dim, need examine to differentiate optic disc, blood vessel.
The long-pending retina major part of III level is blocked, and has only the about 1/4 quadrant structure of periphery to may be seen indistinctly.
IV level optical fundus redness is reflective, and structure loses.
Therapeutic Method:
The A group: medicine of the present invention is formed: by the court pharmaceutical factory unified specification, 1 dose 100 milliliters, divide sooner or later twice clothes after meal.B group: carbazochrome salicylate 5 milliliters of every days 3 times, Catergen 00 milligram of every day 3 times, 10% potassium iodide 10 milliliters of every days 3 times.
Observation index:
1. vision: have an eyesight test before the treatment, continuous 3 months of treatment back is checking eyesight weekly.
2. with ophthalmoscope, three mirror contact lens and eye ultrasound diagnosis, with four degree classification method classification.
3. eye B ultrasonic sight glass volume blood degree, machineization and retina situation.Reach treatment before the treatment and respectively did once in back 1 month, 2 months, 3 months, and stay photo.
4. take pictures and observe clear time of optical fundus, degree in the optical fundus.When seeing, before the treatment and optical fundus respectively takes the photograph one.
More than every ophthalmologic examination be responsible for finishing and the accession designation number of filling in a form by the special messenger.
Treatment standard: become clear degree branch with vitreous body
Cure: the vitreous hemorrhage hypersorption.
Produce effects: most of absorb (residual a little the fine strip shape muddiness) of vitreous hemorrhage.
Effectively: vitreous hemorrhage partially absorbs (residual I level, II level muddiness or a small amount of machineization).
Invalid: vitreous hemorrhage does not have obvious absorption (residual III level muddiness or machineization).
See Table 4, table 5
Two groups of vitreous body situations before and after table 4 treatment
A organizes clear 12 13 I levels, 3 II levels, 1 III level 1
B organizes clear 58 I levels, 6 II levels, 7 III levels 4
Becoming the clear time by the visible A group of table 4 patient treatment rear vitreous body significantly shortens.
By table 5 as seen: Chinese drug-treated group: cure 12 eyes (40.0%), produce effects: 13 eyes (43.3%), effective 4 eyes (13.3%) are invalid: 1 eye (3.3%), Chinese drug-treated group total effective rate 96.7%.Matched group: cure 5 eyes (16.7%), 8 eyes of produce effects (26.7%), effective 13 eyes (43.3%), invalid 4 eyes (13.3%), total effective rate 86.7% is learned by statistics and is handled X
2There is significant difference=10.6375P=0.0139 0.01＜P＜0.05.Check in 3 months, proliferative retinopathy appears in two groups of patients, and 1 eye of A group accounts for 3.3%, and 4 eyes of B group account for 13.3%.
Vision compares: see Table 3
As seen: vision improves fast than the B group behind the A group patient treatment
Model case two examples:
One patient's vitreous hemorrhage IV level, hematocele absorbs the II level, three mirror contact lens inspection, nethike embrane cinerous bulbous protrusions on the temporo after 2 weeks of treatment, see big shape of a hoof fissure cavity, Liquid Absorption under the nethike embrane after the minister bed of being admitted to hospital is had a rest, argon laser sealing fissure cavity continues treatment by Chinese herbs, vision was by manually being increased to 0.2 in 1 month, checking eyesight 0.3 in 3 months, and vitreous hemorrhage absorbs, and leaves a little fine strip shape muddiness.The optical fundus: nethike embrane resets, the fissure cavity sealing, and the macula lutea cephacoria forms.
Patient Liu, the man, 21 years old, left eye was wounded 3 days by iron rod, vision: the right side 1.0, moving/30 centimetres of left hand.The left eye hyphema a little, the pupil moderate is loose big, vitreous hemorrhage IV level, intraocular pressure normal range.Obey medicine of the present invention, vitaminize B
120mg3 time/day, hyphema hypersorption next day, a large amount of red block muddy in the vitreous body, treat the 3rd day vision and increase to 0.1, still do not see the optical fundus, 1 all visions 0.3, the glass volume is equipped with the II level, dim visible optic disc in optical fundus and trunk.The 2nd all hematocele I levels, the optical fundus: visible optic disc nasal side, temporo side nethike embrane deep hemorrhage, macula lutea portion yellow-white oozes out, foveal reflex loses, and continues treatment to 26 days, the vitreous hemorrhage hypersorption, vision restoration to 0.7, macula lutea portion pigment and rigid oozing out, foveal reflex loses.
Toxic and side effects:
Observe in the case in this group, take medicine person of the present invention and any toxic and side effects do not occur.
The chmice acute toxicity test
Summary: give mice two celebratings 270 ml/kg, dosage is equivalent to 162 times of people's feed ration, and mice is not had obvious toxic action, and its mice maximum tolerated dose is greater than 270 ml/kg days.
Key word: mice maximum tolerated dose
Trial drug: medicine of the present invention is provided by Yantai Yuhuangding Hospital, and lot number 980412 is tested preceding 80 degree water-baths and concentrated 1:3 concentration.
Experimental animal: Kunming mouse, institute animal housing of Shandong Province's traditional Chinese medical science pharmacy provides, quality certification Shandong kinoplaszm word 960104.
Test method and result
The trial test mice concentrates back medicinal liquid 0.4 milliliter/10 gram .ig, 10 none poisonings of mice, its movable feed is all normal, there is not death, thus be difficult to measure its LD50, with reference to Ministry of Public Health bureau of drug administration＜study of tcm new drug supplementary provisions 〉, with the maximum tolerated dose method, observe the acute toxicity of medicine, choose 40 of 8-21 gram mices, male and female half and half, by body weight, sex is divided into 2 groups at random, concentrates back medicinal liquid 0.3 milliliter/10 grams respectively in 8 hours after the mice fasting, and water 0.3 milliliter/10 restrains, be administered once in per 4 hours, administration on the one 3 times, the administration of one day are 270 ml/kg original content mixture, one week of medicine successive administration behind the medicine, observe the toxic action of medicine to mice, test group and control group mice all occur unusually as a result, every mice activity, and it is all normal to take food, stool behind medicine 12 hours-24 hours be loose stool, normal after the 3rd day, 40 none death of mice, its two groups of mice body weight change are as shown in table 1 below:
As seen from table, also no significant difference of two groups of weight of mice.
Brief summary and evaluation:
Mice gave this medicine on the 1st and is reaching 270ml/kg, and ig does not have obvious influence to the general situation of mice, none death of laboratory animal, and defecating rare behind the medicine is only to have reached 1.8ml/ because give amount of liquid medicine, of short duration loose stool occurs.Its mice maximum tolerated dose of results suggest〉270ml/1g day.Illustrate that this product do not have the overt toxicity effect.
(4) specific embodiment: following detailed description the present invention also provides several embodiment:
Embodiment 1: with crude drug Radix Salviae Miltiorrhizae 14 grams, Cortex Moutan 8 grams, Radix Paeoniae Rubra 8 grams, Pollen Tyjphae 8 grams, Fructus Leonuri 8 grams, Radix Rehmanniae 22 grams, Radix Angelicae Sinensis 8 grams, Thallus Laminariae (Thallus Eckloniae) 12 grams, Herba Ecliptae 14 grams, Sanguis Draxonis 4 grams, Lignum Dalbergiae Odoriferae 8 grams.The water logging that adds 4 times was steeped 60 minutes, decocted 2 times, and the time of twice decoction was respectively 1.5 hours and 1 hour, merge decocting liquid twice, filtering and concentrating is cooled to room temperature, adds 95% ethanol and makes and contain the alcohol amount and reach 65%, leave standstill and made it abundant precipitation in 24 hours, get supernatant liquid filtering, decompression filtrate recycling ethanol adds 0.4% sodium benzoate aqueous solution, adding distil water is adjusted to 200 milliliters, stirs evenly.
Embodiment 2: with crude drug Radix Salviae Miltiorrhizae 34 grams, Cortex Moutan 22 grams, Radix Paeoniae Rubra 22 grams, Pollen Tyjphae 16 grams, Fructus Leonuri 22 grams, Radix Rehmanniae 50 grams, Radix Angelicae Sinensis 22 grams, Thallus Laminariae (Thallus Eckloniae) 24 grams, Herba Ecliptae 34 grams, Sanguis Draxonis 10 grams, Lignum Dalbergiae Odoriferae 22 grams.The water logging bubble that adds 8 times decocted with water 2 times in 30 minutes, the time of twice decoction was respectively 2.5 hours and 2 hours, merged decocting liquid twice, filtering and concentrating, be cooled to room temperature, add 95% ethanol and make and contain the alcohol amount and reach 70%, leave standstill and made it abundant precipitation in 26 hours, get supernatant liquid filtering and get 0.3～0.7 times of filtrate with raw material weight, decompression filtrate recycling ethanol, add 0.4% sodium benzoate aqueous solution, adding distil water is adjusted to 200 milliliters, stirs evenly.
Embodiment 3: with crude drug Radix Salviae Miltiorrhizae 24 grams, Cortex Moutan 14 grams, Radix Paeoniae Rubra 14 grams, Pollen Tyjphae 12 grams, Fructus Leonuri 14 grams, Radix Rehmanniae 36 grams, Radix Angelicae Sinensis 14 grams, Thallus Laminariae (Thallus Eckloniae) 18 grams, Herba Ecliptae 24 grams, Sanguis Draxonis 7 grams, Lignum Dalbergiae Odoriferae 14 grams.The water logging bubble that adds 6 times decocted 2 times in 50 minutes, the time of twice decoction was respectively 2 hours and 1.5 hours, merged decocting liquid twice, filtering and concentrating, be cooled to room temperature, add 95% ethanol and make and contain the alcohol amount and reach 67%, leave standstill and made it abundant precipitation in 24 hours, get supernatant liquid filtering, decompression filtrate recycling ethanol, add 0.4% sodium benzoate aqueous solution, adding distil water is adjusted to 200 milliliters, stirs evenly.
Claims (6)
1, the medicine of treatment eye vitreous hematocele, muddiness is characterized in that it is the medicament of being made by following raw materials by weight proportions: 7～17% Radix Salviae Miltiorrhizaes, 4～11% Cortex Moutans, 4～11% Radix Paeoniae Rubra, 4～8% Pollen Tyjphae, 4～11% Fructus Leonuris, 11～25% Radix Rehmanniae, 4～11% Radix Angelicae Sinensis, 6～12% Thallus Laminariae (Thallus Eckloniae)s, 7～17% Herba Ecliptaes, 2～5% Sanguis Draxonis, 4～11% Lignum Dalbergiae Odoriferaes.
2, according to the medicine of the described treatment eye vitreous of claim 1 hematocele, muddiness, it is characterized in that it is the medicament of being made by following raw materials by weight proportions: 10～15% Radix Salviae Miltiorrhizaes, 5～10% Cortex Moutans, 5～10% Radix Paeoniae Rubra, 5～7% Pollen Tyjphae, 5～10% Fructus Leonuris, 15～22% Radix Rehmanniae, 5～10% Radix Angelicae Sinensis, 7～11% Thallus Laminariae (Thallus Eckloniae)s, 10～15% Herba Ecliptaes, 2～5% Sanguis Draxonis, 5～10% Lignum Dalbergiae Odoriferaes.
3, according to claim 1 or 2 described treatment eye vitreous hematoceles, muddy medicine, it is characterized in that described medicament is an oral liquid.
4, according to the described treatment eye vitreous of claim 3 hematocele, the preparation method of muddy medicine, it is characterized in that the crude drug Radix Salviae Miltiorrhizae, Cortex Moutan, Radix Paeoniae Rubra, Pollen Tyjphae, Fructus Leonuri, Radix Rehmanniae, Radix Angelicae Sinensis, Thallus Laminariae (Thallus Eckloniae), Herba Ecliptae, Sanguis Draxonis, Lignum Dalbergiae Odoriferae adds 4～8 times water logging bubble at least 30 minutes, decoct 2 times, the time of twice decoction was respectively 1.5～2.5 hours and 1～2 hour, merge decocting liquid twice, filtering and concentrating, be cooled to room temperature, add ethanol and make and contain alcohol amount and reach 65～70%, leave standstill and make it abundant precipitation more than 24 hours or 24 hours, get supernatant liquid filtering, decompression filtrate recycling ethanol, add the sodium benzoate aqueous solution, adding distil water transfers to full dose, stirs evenly.
5, according to the preparation method of the described treatment eye vitreous of claim 4 hematocele, muddy medicine, it is characterized in that described ethanol is 95% alcoholic solution, the sodium benzoate aqueous solution is 0.4% aqueous solution.
6, according to the preparation method of the described treatment eye vitreous of claim 4 hematocele, muddy medicine, it is characterized in that adding distil water transfers to full dose and is meant that the gross weight of filtrate adding distil water is the summation of crude drug weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100236491A CN100500192C (en) | 2004-03-02 | 2004-03-02 | Medicine for treating eye vitreous hemorrhage and turbidity and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100236491A CN100500192C (en) | 2004-03-02 | 2004-03-02 | Medicine for treating eye vitreous hemorrhage and turbidity and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1663588A CN1663588A (en) | 2005-09-07 |
| CN100500192C true CN100500192C (en) | 2009-06-17 |
Family
ID=35035016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100236491A Expired - Fee Related CN100500192C (en) | 2004-03-02 | 2004-03-02 | Medicine for treating eye vitreous hemorrhage and turbidity and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100500192C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102319398B (en) * | 2011-09-26 | 2012-11-28 | 西安碑林药业股份有限公司 | Blood-nourishing and eyesight-improving Chinese medicinal composition and preparation method thereof |
| CN106266033A (en) * | 2016-08-31 | 2017-01-04 | 王�华 | A kind of preparation method of conjunctival hemorrhage eye sticker |
-
2004
- 2004-03-02 CN CNB2004100236491A patent/CN100500192C/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| 玻璃体积血的中西医研究概况. 李建国，张琳.湖南中医学院学报，第21卷第4期. 2001 |
| 玻璃体积血的中西医研究概况. 李建国，张琳.湖南中医学院学报，第21卷第4期. 2001 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1663588A (en) | 2005-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102145126B (en) | Pharmaceutical composition for treating xerophthalmia | |
| CN102579840A (en) | Chinese medicinal composition with effects of reducing intraocular pressure and protecting optic nerves and preparation method thereof | |
| Langham et al. | Horner's syndrome: Ocular supersensitivity to adrenergic amines | |
| CN104971304A (en) | Xerophthalmia treatment medicine | |
| Mann et al. | Amantadine for Parkinson's disease | |
| CN101700379B (en) | Traditional Chinese medicine preparation for treating central serous chorioretinopathy | |
| CN100500192C (en) | Medicine for treating eye vitreous hemorrhage and turbidity and its preparation method | |
| CN101361892B (en) | Traditional Chinese medicine formulation for treating cataract and preparation method thereof | |
| KR20180041232A (en) | A medicinal composition for treating diabetic retinopathy | |
| CN109865016A (en) | A kind of pharmaceutical composition and its preparation method and application for treating xerophthalmia | |
| CN112121104B (en) | Traditional Chinese medicine composition for relieving asthenopia and preventing and treating myopia | |
| CN102210841B (en) | Chinese medicinal preparation for treating central serous retinopathy | |
| CN112294963B (en) | Pharmaceutical composition for treating age-related macular degeneration | |
| CN100577187C (en) | Chinese medicine preparation for treating eye fatigue and its preparing process | |
| CN102631623A (en) | Traditional Chinese medicine composite for treating thyroid associated ophthalmopathy and preparation method thereof | |
| CN103055112B (en) | Traditional Chinese medicine compound composition for treating uveitis | |
| CN1061251C (en) | Blood circulation promoting capsule for hemalopia | |
| CN104306546A (en) | A traditional Chinese medicine composition used for treating optic atrophy, and decoctions, pills and powder of the composition | |
| CN107714709A (en) | Otoginsenoside and its salt are preparing the purposes in treating cataract medicine | |
| CN109663100A (en) | A kind of Chinese medicine composition and its preparation method and application for treating optic neuritis | |
| Chmielarz-Czarnocińska et al. | Ophthalmic applications of cyclopentolate | |
| CN106668240A (en) | Pharmaceutical composition for treating vitreous opacity | |
| CN1073600A (en) | The preparation method of the Chinese medicine preparation of treatment pseudomyopia | |
| CN100443093C (en) | AIDS treating medicine | |
| CN1222304C (en) | Medicine for treating turbid vitrious body and its prepn |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090617 Termination date: 20110302 |